Valneva's 15-min chart shows Bollinger Bands narrowing, KDJ death cross, and bearish Marubozu.

Valneva's 15-minute chart has triggered a narrowing of Bollinger Bands, a KDJ Death Cross, and a bearish Marubozu at 10/10/2025 14:15. This indicates a decrease in the magnitude of stock price fluctuations, a shift in momentum towards the downside with a potential for further decrease, control of the market by sellers, and a continuation of bearish momentum.

Valneva SE (NASDAQ: VALN) saw its shares fall by 7% after the French biopharmaceutical company delayed the release of Phase 3 data for its Lyme disease vaccine and cut its 2025 financial guidance. The stock's decline was further exacerbated by the FDA's suspension of the product license for its IXCHIQ vaccine Valneva stock falls after FDA suspension forces guidance cut^[2].

The delay in the Phase 3 data release, initially expected in late 2025, is now projected to occur in the first half of 2026. This delay has led Valneva to revise its annual revenue expectations from €180-190 million to €165-180 million, a decrease of €15-25 million. Additionally, the company has reduced its research and development (R&D) investments from €90-100 million to €80-90 million Valneva falls after Lyme disease vaccine data delay, outlook cut^[1].

Valneva's stock is on track for its worst day in six weeks if the losses hold, with the company citing ongoing uncertainty as it awaits further information from the FDA regarding the IXCHIQ suspension. Despite the guidance reduction, Valneva noted that its commercial business is still expected to be cash flow positive.

In a separate announcement, Valneva revealed it has secured a debt facility for up to $500 million with Pharmakon Advisors, LP. This new financing extends Valneva’s debt repayment timeline from Q1 2026 to Q4 2030, while also offering more favorable terms including a lower interest rate and improved structure with bullet maturity after five years Valneva stock falls after FDA suspension forces guidance cut^[2].

The Phase 3 clinical trial of Valneva's Lyme disease vaccine candidate, being developed with Pfizer (NYSE: PFE), remains on track. The companies still aim to submit regulatory applications in 2026, with a potential launch in the second half of 2027 pending approval Valneva stock falls after FDA suspension forces guidance cut^[2].